Etsuyo Ogo, Takeshi Arimura, Takashi Ogino, Uhi Toh, Kenta Murotani, Ichiro Isomoto, Makoto Kubo, Reiki Nishimura, Yusaku Miyata, Gen Suzuki, Yoshio Hishikawa, Shoshu Mitsuyama, Ryoichi Nagata
Preliminary clinical observations suggest that PB-PBT without lumpectomy achieves results within specific criteria and that it could be an option for breast cancer treatment using radiation therapy alone.
BACKGROUND: We report on our initial clinical experience with partial breast proton beam therapy (PB-PBT) without tumor resection as an alternative to partial mastectomy for low-risk early-stage breast cancer.
METHODS: This trial commenced in 2015, and eligibility criteria included women with cT1N0M0 invasive ductal carcinoma, estrogen receptor positivity, human epidermal growth factor receptor type-2 negativity, age of 40-70 years, and a performance status of 0 or 1. In Phase I, PB-PBT was administered at 62.4 Gy (RBE) in 26 fractions using the field-in-field technique. After confirming that no serious adverse events occurred, Phase II was conducted using the same dose. Follow-up evaluations were conducted every 3 months for the first year after irradiation and every 6 months thereafter.
RESULTS: As of December 2025, 11 patients had completed a follow-up of ≥ 5 years. The median follow-up time was 82 months. Tumors exhibited immediate shrinkage post-PB-PBT, with morphological changes on ultrasonography and magnetic resonance imaging observed within 3-6 months. No recurrence was observed within the irradiated field in patients with > 5 years of follow-up. Dermatitis was Grade 1 in 55% of cases and Grade 2 in 45%; there were no cases of Grade ≥ 3. Grade 1 telangiectasia was observed in 36% of patients after 2 years, although most patients tolerated the treatment well.
CONCLUSION: Preliminary clinical observations suggest that PB-PBT without lumpectomy achieves results within specific criteria and that it could be an option for breast cancer treatment using radiation therapy alone.